REGN Earnings Date: Jan 29, 2027 (Estimated) — Regeneron Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is REGN's next earnings date?
Regeneron Pharmaceuticals, Inc. (REGN) is expected to report Q4 2026 earnings on Friday, January 29, 2027 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $14.96 on revenue of $4.60B.
How did REGN do in its last earnings report?
In its most recent report on Oct 30, 2026 (Q3 2026), Regeneron Pharmaceuticals, Inc. posted EPS of $20.07 versus the $16.42 estimate, a beat of 22.2%. Revenue was $5.12B against a $4.56B estimate.
How much does REGN stock move after earnings?
REGN beat EPS estimates in 7 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 5.6% (up or down) in the day after earnings.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
🤖 AI Earnings Analysis
Regeneron delivered a strong biotech quarter, with revenue up 99.2% to $5.1B and EPS of $20.07 beating estimates by $3.65. The outsized growth is compelling, though the provided headlines identify no separate catalyst.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-30 | Q3 2026 | 16.42 | 20.07 | +22.23% | $5.12B | ✅ Beat | — | — | — |
| 2026-07-30 | Q2 2026 | 10.34 | 14.29 | +38.20% | $4.29B | ✅ Beat | +6.17% | +10.52% | +16.28% |
| 2026-04-29 | Q1 2026 | 8.38 | 9.47 | +13.01% | $3.60B | ✅ Beat | -6.21% | -4.03% | -14.94% |
| 2026-01-30 | Q4 2025 | 9.69 | 11.44 | +18.06% | $3.88B | ✅ Beat | -1.07% | +2.29% | +5.65% |
| 2025-10-28 | Q3 2025 | 8.84 | 11.83 | +33.82% | $3.75B | ✅ Beat | +11.82% | +9.73% | +34.68% |
| 2025-08-01 | Q2 2025 | 7.55 | 12.89 | +70.73% | $3.68B | ✅ Beat | +2.46% | +2.63% | +6.62% |
| 2025-04-29 | Q1 2025 | 8.82 | 8.22 | -6.80% | $3.03B | ❌ Miss | -6.87% | -1.19% | -2.97% |
| 2025-02-04 | Q4 2024 | 11.19 | 12.07 | +7.86% | $3.79B | ✅ Beat | +4.53% | +3.53% | +3.18% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q3 FY26 · $5.12B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Collaboration Revenue | 58.7% | $3.00B | +52.4% | $1.53B | $1.86B | $1.97B | $1.97B |
| Product | 35.3% | $1.81B | +13.7% | $1.42B | $1.63B | $1.59B | $1.67B |
| Product and Service, Other | 6.1% | $310.0M | +56.4% | $81.9M | $183.9M | $198.2M | $238.6M |
By region
Q3 FY26 · $1.25B total
| Segment | Share | Revenue | YoY | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 87.7% | $1.10B | -1.1% | $3.27B | $941.5M | $1.01B | $1.10B |
| Rest Of World | 12.3% | $154.2M | +5.5% | $361.4M | $152.1M | $146.8M | $154.2M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.